Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Is Acadia Pharmaceuticals a Buy?
11:27am, Tuesday, 02'nd Jun 2020
A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.
ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
01:04pm, Thursday, 28'th May 2020ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer
01:00pm, Thursday, 28'th May 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Busine
ACADIA to Merge Two Phase III Studies on Nuplazid for MDD
04:15pm, Wednesday, 27'th May 2020
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $53
12:27pm, Wednesday, 27'th May 2020Stocks Will Try To Rise On May 27 On More Stimulus Hopes
12:00am, Wednesday, 27'th May 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3
Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT
03:28am, Friday, 22'nd May 2020
Q1 2020 ACADIA Pharmaceuticals Inc Earnings Call
ACADIA Pharma Will Present Pimavanserin Data At American Society Of Clinical Psychopharmacology Meeting May 29-30
01:04pm, Thursday, 21'st May 2020
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous
